Assessment of Serum ST2 Receptor Levels in Female Coronary Artery Disease Patients with LV Dysfunction in Comparison to Males
Background Heart failure is shown to be associated with elevated levels of ST2 levels in blood. The data about the relation of blood ST2 levels, in patients of significant coronary artery disease (CAD) with left ventricular (LV) dysfunction is limited. The impact of gender on ST2 levels not studied until now, so this study aimed to assess the blood ST2 levels measured for males and females patients in comparisons, of CAD with LV dysfunction and their relation to the outcomes at the end of 1-year post intervention.
Material and Methods Out of the 60 patients with 1:2 ratio of females and males with CAD and LV dysfunction, baseline quantitative assessment of ST2 levels in blood was done by rapid lateral flow immunoassay method; > 35 mg/mL was considered as abnormal. Postintervention patients followed up to one year, adverse cardiovascular events noted at the end of 1 year. By using binary logistic regression, the outcomes in females compared with males for statistical significance in relation to baseline blood ST 2 levels. The p value of < 0.05 considered was significant.
Results Among the 60 patients (females 33.3% and males 66.6 %) presented with CAD with LV dysfunction in the study, 40 (66.6 %) patients diagnosed of acute coronary syndrome (ACS), and 20 (33.3%) patients with chronic stable angina (CSA). In both the genders, ACS is most common presentation (55% in females and 72.5 % in males). Eighteen (90%) females and 20 (50%) males were hypertensive, 12 (60%) females and 18 (45%) males were diabetics. Twenty-seven (67.5%) males were smokers and 14 (35%) were alcoholics. Nine (45%) female and 14 (35%) male patients had elevated ST2 levels. At the end of 1 year 9 females had events including 2 mortalities, 2 heart failures, and 7 repeat revascularizations. At the same time 7 male patients had events at the end of 1 year including 4 mortalities, 5 heart failures, and 2 repeat revascularizations. The difference in the event rates between male and female patients were statistically significance (p = 0.03). Elevated ST2 levels were correlated with echocardiographic parameter end systolic volume which was statistically significant (p= 0.03). Similarly elevated ST2 levels correlated with presence of diabetes (p= 0.01) and low LV EF.
Conclusion Mean Blood ST2 levels were higher in females who associated with diabetes, high echo cardio graphic end-systolic volume, and a low ejection fraction of LV in severe LV dysfunction with statistical significance. At the end of 1 year in patients with elevated baseline ST2 levels, the female patient had more events than males with statistical significance.
28 July 2020 (online)
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154 (02) 260-266
- 2 Pascual-Figal DA, Januzzi JL. The biology of ST2: The international ST2 consensus panel. Am J Cardiol 2015; 115 (Suppl. 07) 3B-7B
- 3 Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 1989; 258 (02) 301-304
- 4 Weinberg EO, Shimpo M, De Keulenaer GW. et al Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002; 106 (23) 2961-2966
- 5 Schmitz J, Owyang A, Oldham E. et al IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23 (05) 479-490
- 6 Yancy CW, Jessup M, Bozkurt B. et al WRITING COMMITTEE MEMBERS; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128 (16) e240-e327
- 7 Socrates T, deFilippi C, Reichlin T. et al Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 2010; 268 (05) 493-500
- 8 Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40 (05) 976-982
- 9 Kohli P, Bonaca MP, Kakkar R. et al Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012; 58 (01) 257-266
- 10 Januzzi JL, Pascual-Figal D, Daniels LB. ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol 2015; 115 (07) (Suppl) 70B-75B
- 11 Tseng CCS, Huibers MM, van Kuik J, de Weger RA, Vink A, de Jonge N. The interleukin-33/ST2 pathway is expressed in the failing human heart and associated with profibrotic remodeling of the myocardium. J Cardiovasc Transl Res 2018; 11 (01) 15-21
- 12 Sabatine MS, Morrow DA, Higgins LJ. et al Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008; 117 (15) 1936-1944
- 13 Weir RA, Miller AM, Murphy GE. et al Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010; 55 (03) 243-250
- 14 Kunwar BK, Hooda A, Joseph G. Recent trends in reperfusion in ST elevation myocardial infarction in a South Indian tier-3 city. Indian Heart J 2012; 64 (04) 368-373
- 15 Xavier D, Pais P, Devereaux PJ. et al CREATE registry investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008; 371 (9622) 1435-1442
- 16 Coglianese EE, Larson MG, Vasan RS. et al Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012; 58 (12) 1673-1681
- 17 Miller AM, Purves D, McConnachie A. et al Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?. PLoS One 2012; 7 (10) e47830
- 18 Omar F. et al Soluble ST2 in heart failure with preserved ejection fraction. J Am Heart Assoc 2017; 6: e004382